[Ezetimibe (Ezetrol) in patients with diabetes].

Abstract

Ezetimibe (Ezetrol) selectively inhibits the intestinal absorption of cholesterol and phytosterols. Its mechanism of action results in a synergistic cholesterol-lowering effect together with a statin that inhibits cholesterol synthesis by the liver, which leads to the development of a fixed ezetimibe-simvastatin combination (Inegy). Ezetimibe has been more particularly studied in patients with type 2 diabetes whose high cardiovascular risk is well known. The present article aims at describing recent advances and specificities concerning the use of ezetimibe in the diabetic population.

• Authors: A J Scheen, R P Radermecker
• Journal: Revue medicale de Liege (Rev Med Liege) Vol. 64 Issue 12 Pg. 606-11 (Dec 2009) ISSN: 0370-629X [Print] Belgium
• Vernacular Title: Ezétimibe (Ezetrol) chez le patient diabétique.
• PMID: 20143743 (Publication Type: English Abstract, Journal Article)

Chemical References

• Anticholesteremic Agents
• Azetidines
• Cholesterol, LDL
• Ezetimibe

Topics

• Anticholesteremic Agents (pharmacology, therapeutic use)
• Azetidines (pharmacology, therapeutic use)
• Cardiovascular Diseases (etiology, prevention & control)
• Cholesterol, LDL (metabolism)
• Diabetes Mellitus, Type 2 (complications)
• Ezetimibe
• Humans
• Intestinal Absorption (drug effects)